Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a progressive disease, with increasing insulin resistance (IR) (tied to obesity and/or adiposity) and deteriorating beta-cell function being key pathophysiologic defects in the development and worsening of hyperglycemia.

Based on the understanding of the pathogenesis of T2DM, several distinct pharmacological therapies have been developed. Within this armamentarium, dipeptidyl peptidase-4 (DPP-4) inhibitors are the most recent addition to the oral treatment options available in clinical practice for the treatment of T2DM.

The DPP-4 enzyme rapidly inactivates the incretin hormones, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) \[[@CR1]\], which play a crucial role in glucose homeostasis \[[@CR2], [@CR3]\]. DPP-4 inhibitors bind to the catalytic site of DPP-4, resulting in prolonged inhibition of the enzyme, thus, raising levels of intact GLP-1 and GIP \[[@CR4]\]. The resulting improvement in islet dysfunction is a key mechanism underlying the glucose-lowering mechanism of DPP-4 inhibitors \[[@CR4]\]. There is also a potential beta-cell preservation effect, as judged from rodent models, in which an increase in beta-cell mass through stimulation of neogenesis and proliferation, as well as an inhibition of apoptosis, has been seen with GLP-1/DPP-4 inhibitors \[[@CR5], [@CR6]\].

While DPP-4 inhibitor therapy has been studied in a variety of clinical study settings \[[@CR7]--[@CR10]\], the optimal stage for their use in the course of T2DM is still under debate. Based on the known effects on beta-cell function, there is frequently a perception that treatment with these agents may be less efficacious with increasing disease progression, due to loss of beta-cell function, and with increasing IR, where beta-cell function is proportionally less important.

The present paper, therefore, aimed to evaluate the impact of such factors (i.e., T2DM duration and duration of previous therapy, and IR and body mass index \[BMI\]) on the efficacy of the DPP-4 inhibitor, vildagliptin, using a pooled database of studies in add-on therapy to metformin. Vildagliptin is a DPP-4 inhibitor that has been extensively studied in a large clinical program, with proven efficacy and a well-established safety profile \[[@CR8], [@CR11]--[@CR14]\]. The present paper reports the results of these new pooled subgroup analyses with vildagliptin.

Methods {#Sec2}
=======

Populations {#Sec3}
-----------

The efficacy analyses included all randomized, double-blind, controlled, parallel-group add-on to metformin studies with vildagliptin 50 mg twice daily (b.i.d.) (the highest approved and most commonly used dose of the drug). A total of four studies were pooled (termed 'pooled add-on to metformin population'). The efficacy population comprised all patients who were included in the respective primary efficacy populations of the individual studies \[[@CR15]--[@CR18]\]. Data collected in the first 24 weeks of treatment from these studies were included in the analyses. Details of the study designs are summarized in Appendix Table [3](#Tab3){ref-type="table"} and the individual study publications \[[@CR15]--[@CR18]\].

Assessments {#Sec4}
-----------

Hemoglobin A~1c~ (HbA~1c~) was measured regularly in all studies. The laboratory assessments were performed by central laboratories: Bioanalytical Research Corporation-EU (Ghent, Belgium), Diabetes Diagnostics Laboratory (Columbia, MO, US), and Covance (Geneva, Switzerland, Singapore, or Indianapolis, IN, US).

Homeostasis model assessment IR (Homa IR) was calculated based on the following formula: Homa IR = (fasting insulin \[μU/mL\]) × (fasting glucose \[mmol/L\])/22.5. Glomerular filtration rate (GFR) was estimated by the Modification of Diet in Renal Disease study method (MDRD) \[[@CR19]\].

Data Analysis {#Sec5}
-------------

The total number of patients, and demography and baseline characteristics were recorded.

Efficacy analyses were stratified according to baseline IR stage (Homa IR \<5 and ≥5), BMI (\<27, ≥27 to \<30, ≥30 kg/m^2^), T2DM duration (0 to \<1, ≥1 to \<5, ≥5 years), and duration of metformin use (0 to \<1, ≥1 to \<5, ≥5 years). Mean changes from baseline in HbA~1c~ at the week 24 endpoint in the defined subgroups were analyzed using last observation carried forward (LOCF). Within-group comparisons (endpoint vs. baseline) were made using one-sample *t* test at a significance level of 0.05.

Efficacy data are reported for vildagliptin 50 mg b.i.d. (*n* = 2,478), with data from patients treated with a sulfonylurea (SU) in the pooled studies being provided as reference (*n* = 2,010). While the SU group had a comparable number of patients to the vildagliptin group, the two other comparator groups in the studies (placebo and thiazolidinedione \[TZD\]) comprised only 2.6% and 5.7%, respectively, of patients in the pooled population; thus, not representing meaningful reference groups to be analyzed.

Ethics and Good Clinical Practice {#Sec6}
---------------------------------

All study participants provided written informed consent. All protocols were approved by the independent ethics committee/institutional review board at each study site or country. All studies were conducted using good clinical practice and in accordance with the Declaration of Helsinki.

Results {#Sec7}
=======

Demography {#Sec8}
----------

Table [1](#Tab1){ref-type="table"} summarizes the demographic and baseline characteristics of patients in the pooled add-on to metformin population. The population studied was representative of a broad spectrum of T2DM patients, with a mean age of 58 years, mean HbA~1c~ of 7.7%, mean fasting blood glucose (FPG) of 9.6 mmol/L, mean BMI of 32 kg/m^2^, and mean Homa IR of 4.3, respectively. The mean duration of diagnosed T2DM was 5.9 years, with a mean duration of metformin use of 3.0 years. Approximately 30% of patients had renal impairment (mostly mild), \>65% had hypertension, and about 50% had dyslipidemia. The majority of patients (\>80%) were Caucasian. The demographic and baseline characteristics were comparable across the vildagliptin group and the SU reference group.Table 1Demography and baseline characteristics (pooled add-on to metformin population)Mean ± SD or *n* (%)Vilda 50 mg b.i.d. + metforminSU + metformin*n*2,4782,010Age (years)57.5 ± 9.458.0 ± 9.5 ≥65638 (25.7)595 (29.6)Sex Male1,347 (54.4)1,070 (53.2) Female1,131 (45.6)940 (46.8)Race Caucasian2,089 (84.3)1,691 (84.1) Black43 (1.7)25 (1.2) Asian103 (4.2)86 (4.3) Hispanic/Latino227 (9.2)190 (9.5) All other16 (0.6)18 (0.9)*n*2,4772,010 HbA~1c~ (%)7.7 ± 1.07.6 ± 0.9*n*2,4752,009 FPG (mmol/L)9.7 ± 2.59.5 ± 2.5*n*2,4722,003 BMI (kg/m^2^)31.9 ± 5.331.5 ± 5.2  ≤27465 (18.8)421 (20.9)  ≤301,022 (41.2)878 (43.7)  \>301,450 (58.5)1,125 (56.0)  \>35651 (26.3)468 (23.3)  Not recorded6 (0.2)7 (0.3)*n*2,1211,703 Homa IR4.4 ± 4.24.2 ± 3.7  \<51,519 (61.3)1,267 (63.0)  ≥5602 (24.3)436 (21.7)  Not recorded357 (14.4)307 (15.3)*n*2,4782,010 Duration of T2DM (years)5.9 ± 5.16.0 ± 5.1  0 to \<1237 (9.6)202 (10.0)  ≥1 to \<51,079 (43.5)850 (42.3)  ≥51,162 (46.9)958 (47.7)*n*2,4772,010 Duration of metformin use (years)3.0 ± 3.03.0 ± 2.9  0 to \<1713 (28.8)591 (29.4)  ≥1 to \<51,294 (52.2)1,047 (52.1)  ≥5470 (19.0)372 (18.5)  Not recorded1 (0.0)0 (0.0)*n*2,4782,010 Medical history GFR (MDRD) (mL/min) per (1.73 m^2^)  Normal1,713 (69.1)1,367 (68.0)  Mild (≥50, ≤80)739 (29.8)626 (31.1)  Moderate (≥30, ≤50)23 (0.9)17 (0.8)  Severe (\<30)2 (0.1)0 (0.0)  Not recorded1 (0.0)0 (0.0) Hypertension1,586 (64.0)1,375 (68.4) Dyslipidemia1,279 (51.6)992 (49.4)*b.i.d.* twice daily, *BMI* body mass index, *FPG* fasting plasma glucose, *GFR* glomerular filtration rate, *HbA*~*1c*~ hemoglobin A~1c~, *Homa IR* homeostasis model assessment insulin resistance, *MDRD* Modification of Diet in Renal Disease, *SU* sulfonylurea, *T2DM* type 2 diabetes mellitus, *Vilda* vildagliptin

Efficacy by Subgroups {#Sec9}
---------------------

Table [2](#Tab2){ref-type="table"} displays mean changes from baseline to week 24 in HbA~1c~ with vildagliptin 50 mg b.i.d. according to Homa IR, BMI, T2DM duration, and duration of metformin use in the pooled add-on to metformin population.Table 2Efficacy (HbA~1c~ \[%\]) by Homa IR, BMI, T2DM duration and duration of metformin useVilda 50 mg b.i.d. + metforminSU + metforminBLMean ∆BLMean ∆BL Homa IR*n*1,5071,237\<5 (mean = 2.8/2.7)7.63 ± 0.02−0.65 ± 0.02\*7.51 ± 0.03−0.76 ± 0.02\**n*598428≥5 (mean = 8.6/8.3)8.07 ± 0.05−0.68 ± 0.04\*7.80 ± 0.05−0.77 ± 0.05\*BL BMI*n*444398\<27 kg/m^2^ (mean = 24.9/25.1)7.80 ± 0.05−0.67 ± 0.04\*7.66 ± 0.05−0.80 ± 0.04\**n*556453≥27 to \<30 kg/m^2^ (mean = 28.5/28.4)7.74 ± 0.04−0.67 ± 0.04\*7.59 ± 0.04−0.79 ± 0.04\**n*1,4461,106≥30 kg/m^2^ (mean = 35.3/35.1)7.72 ± 0.03−0.63 ± 0.02\*7.58 ± 0.03−0.73 ± 0.03\*BL T2DM duration*n*2361980 to \<1 year (mean = 0.6/0.6)7.47 ± 0.06−0.64 ± 0.05\*7.32 ± 0.06−0.73 ± 0.06\**n*1,061829≥1 to \<5 years (mean = 2.9/2.9)7.65 ± 0.03−0.60 ± 0.03\*7.49 ± 0.03−0.71 ± 0.03\**n*1,155936≥5 years (mean = 9.7/9.8)7.88 ± 0.03−0.69 ± 0.03\*7.75 ± 0.03−0.80 ± 0.03\*BL duration of metformin use*n*7095800 to \<1 year (mean = 0.6/0.6)7.70 ± 0.04−0.63 ± 0.03\*7.53 ± 0.04−0.75 ± 0.04\**n*1,2741,022≥1 to \<5 years (mean = 2.6/2.6)7.70 ± 0.03−0.63 ± 0.02\*7.58 ± 0.03−0.74 ± 0.03\**n*468361≥5 years (mean = 7.9/7.7)7.93 ± 0.05−0.70 ± 0.04\*7.76 ± 0.05−0.82 ± 0.05\*Data are mean ± SE*b.i.d.* twice daily, *BL* baseline, BMI body mass index, *HbA*~*1c*~ hemoglobin A~1c~, *Mean ∆* mean change from BL, *n* number of patients with observations at both baseline and endpoint, *SU* sulfonylurea, *T2DM* type 2 diabetes mellitus, *Vilda* vildagliptin\* *P* \< 0.0001

The influence of IR on the efficacy of vildagliptin was assessed by stratification according to two baseline Homa IR categories, Homa IR \<5 (mean = 2.8) and Homa IR ≥5 (mean = 8.6). In addition, three BMI categories were analyzed, BMI \<27 kg/m^2^ (mean = 24.9 kg/m^2^), ≥27 to \<30 kg/m^2^ (mean = 28.5 kg/m^2^), and ≥30 kg/m^2^ (mean = 35.3 kg/m^2^). HbA~1c~ was reduced to a very similar extent independent of baseline Homa IR or BMI category. For example, HbA~1c~ (± SE) was reduced by −0.67 ± 0.04% (baseline 7.80 ± 0.05%), −0.67 ± 0.04% (baseline 7.74 ± 0.04%), and −0.63 ± 0.02% (baseline 7.72 ± 0.03%) in the BMI subgroups of \<27, ≥27 to \<30, and ≥27 kg/m^2^, respectively.

The impact of disease progression on the efficacy of vildagliptin was evaluated by stratification according to three T2DM duration categories, 0 to \<1 year (mean = 0.6 years), ≥1 to \<5 years (mean = 2.9 years), and ≥5 years (mean = 9.7 years). In addition, the duration of metformin use was considered, with categories of 0 to \<1 year (mean = 0.6 years), ≥1 to \<5 years (mean = 2.6 years), and ≥5 years (mean = 7.9 years). Patients with shorter and longer duration of T2DM and metformin use had very similar decreases in HbA~1c~. For example, HbA~1c~ (±SE) was reduced by −0.64 ± 0.05% (baseline 7.47 ± 0.06%), −0.60 ± 0.03% (baseline 7.65 ± 0.03%), and −0.69 ± 0.03% (baseline 7.88 ± 0.03%) in the T2DM duration subgroups of 0 to \<1, ≥1 to \<5, and ≥5 years, respectively.

Table [2](#Tab2){ref-type="table"} also displays efficacy results in the different sub-categories for the SU reference group. The results in patients receiving a SU were comparable to those seen in the vildagliptin group, with similar HbA~1c~ reductions across the different Homa IR, BMI, T2DM duration, and duration of metformin use subgroups.

Discussion {#Sec10}
==========

The present paper evaluated the impact of IR, BMI, disease duration, and duration of metformin use on the efficacy of vildagliptin in patients with T2DM treated with metformin. The pooled analysis found similar efficacy of vildagliptin independent of these factors, indicating that patients with higher IR, more obese patients, and patients with long-standing T2DM can benefit from treatment with the DPP-4 inhibitor, vildagliptin, in combination with metformin.

These data can provide relevant information for the use of vildagliptin in clinical practice, in particular given the not uncommon perception that treatment with DPP-4 inhibitors may be less beneficial with increasing disease progression, due to loss of beta-cell function, and with increasing IR, where beta-cell function is proportionally less important. The notion of DPP-4 inhibitors being more beneficial in patients with shorter disease duration may at least be in part related to the promise from animal models \[[@CR5], [@CR6]\] that these incretin-based therapies may be able to interfere with disease progression if used as an early intervention, when sufficient beta-cell function/mass can be still be preserved or restored, which raised particular attention when these drugs initially became available. On the other hand, consistent with the findings of the present report, vildagliptin has meanwhile been shown to be efficacious across a wide disease spectrum, including add-on therapy to insulin as well as patients with renal impairment, both involving patients with long-standing T2DM (mean T2DM duration 13--17 years) \[[@CR20]--[@CR23]\].

In this context, it is important to keep in mind that vildagliptin, in addition to improving beta-cell function, also enhances alpha-cell function (i.e., suppresses inappropriate glucagon secretion as shown after oral glucose and meal ingestion \[[@CR24]--[@CR26]\]), with the changes in islet hormone (i.e., increased insulin and reduced glucagon) secretion leading to a profound effect to suppress hepatic glucose production \[[@CR27]\]. Furthermore, vildagliptin is associated with reduced insulin resistance due to reduced lipotoxicity \[[@CR28], [@CR29]\]. Thus, a variety of pancreatic and extra-pancreatic effects are active to support the efficacy of vildagliptin \[[@CR4]\].

Similar results to those seen with vildagliptin plus metformin were also seen in the group of patients treated with SUs in combination with metformin, who were analyzed as a reference group. The common perception is that both DPP-4 inhibitors and SUs tend to be more efficacious in lean than obese individuals and the reverse is true for TZDs. The data in this study do not support this perception about vildagliptin and SUs, and the authors are unaware of any data that does. In contrast, addition of the TZD, rosiglitazone, to metformin was indeed shown to be most efficacious in obese, insulin-resistant patients, as expected from the mechanism of action \[[@CR30]\]. Similar results were also seen with pioglitazone added to SU therapy in a small Japanese study; HbA~1c~ was decreased considerably more in the Homa IR ≥4 category compared to the \<4 subgroup \[[@CR31]\]. The current study does not address the question of whether a longer duration of SU use is associated with a reduced response, but indicates that addition of SUs to patients with a longer duration of T2DM is not associated with reduced efficacy. This is in contrast to one open-label study of glimepiride monotherapy \[[@CR32]\], which showed a weak association of longer duration of diabetes with the likelihood of being a nonresponder (odds ratio \[OR\] = 1.096); however, the study was confounded by a strong correlation with previous oral antidiabetic drug (OAD) treatment (OR = 2.506).

In light of the applicability of the reported results, it is important to note that each of the categories investigated included a broad range of vildagliptin-treated patients, with means of IR categories from 2.8 to 8.6, of BMI from 24.9 to 35.3 kg/m^2^, and of disease duration from \<1 year to nearly 10 years (overall range 0.1--40.1 years). Another important factor for the interpretation of the subgroup results is that HbA~1c~ levels were well matched between the different categories, which is an important consideration given that HbA~1c~ levels strongly influence response to treatment. Since metformin was used as a background drug, some limitations of the clinical applicability of the present results to other indications cannot be ruled out, and it will be of interest to investigate whether similar results will be seen with vildagliptin in combination with other drugs, as well as in monotherapy. While no such data are currently available for the subgroups of disease duration or IR stage, in a study with vildagliptin monotherapy in patients with mild hyperglycemia, the same treatment effect was seen in patients with baseline BMI \< 30 and ≥30 kg/m^2^ \[[@CR33]\].

Conclusion {#Sec11}
==========

Taken together, the present pooled analysis provides a comprehensive assessment of the efficacy of vildagliptin in subgroups of IR stage and BMI, as well as disease duration and duration of prior metformin use, showing similar efficacy of vildagliptin across a wide spectrum of these categories.
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Appendix {#Sec25}
========

###### 

Vildagliptin add-on to metformin studies contributing to analyses

  Study No.   Study description                                                                                                                             Randomized patients   Treatment duration (weeks)   Publication
  ----------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ---------------------------- ----------------------
  1           Placebo-controlled efficacy/safety study in T2DM patients inadequately controlled with metformin (HbA~1c~ 7.5--11%)                           544                   24                           \[[@CR15]\]
  2           Active-controlled (glimepiride) long-term efficacy/safety study in T2DM patients treated with metformin (HbA~1c~ \>6.5--8.5%)                 3,118                 ≥104                         \[[@CR16], [@CR34]\]
  3           Active-controlled (gliclazide) long-term efficacy/safety study in T2DM patients inadequately controlled with metformin (HbA~1c~ 7.5--11%)     1,007                 52                           \[[@CR17]\]
  4           Active-controlled (pioglitazone) long-term efficacy/safety study in T2DM patients inadequately controlled with metformin (HbA~1c~ 7.5--11%)   576                   52                           \[[@CR18], [@CR35]\]

*HbA*~*1c*~ hemoglobin A~1c~, *T2DM* type 2 diabetes mellitus
